Serum CD10 is associated with liver metastasis in colorectal cancer. 2014

Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan.

BACKGROUND Colorectal cancer (CRC) is the third leading cause of cancer death in Japan. CD10 expression is closely associated with liver metastasis. In the present study, we explored the possibility of serum CD10 as a marker of liver metastasis in CRC. METHODS BALB/c mouse with subcutaneous tumor of syngeneic CT26 CRC cells were examined serum CD10. In 84 CRC patients and patients undergoing hemodialysis, serum CD10 was examined. CD10 concentration was measured by enzyme-linked immunosorbent assay. RESULTS In a mouse subcutaneous tumor model, serum CD10 correlated with the weight of the tumors. Serum CD10 was examined in 84 patients with CRC. The serum levels of CD10 were higher in patients with more advanced cancer stages. Patients with liver metastasis showed the highest levels of serum CD10 among all patients. Importantly, patients with high serum CD10 levels had metachronous liver metastasis. Healthy volunteers showed low levels of CD10; however, serum CD10 levels in patients undergoing hemodialysis showed levels as high as those with stage II and III CRC. A cutoff of serum CD10 set to >1000 pg/mL showed 70% sensitivity and 93% specificity for liver metastasis in CRC. This cutoff included all cases of metachronous liver metastasis. CONCLUSIONS With the exclusion of mimicking factors, serum CD10 levels might serve as a useful marker of synchronous and metachronous liver metastasis in CRC.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015260 Neprilysin Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT. Antigens, CD10,Antigens, Leukemia, Common Acute Lymphoblastic,CALLA Antigen,CD10 Antigens,Common Acute Lymphoblastic Leukemia Antigens,Endopeptidase-24.11,Enkephalin Dipeptidyl Carboxypeptidase,Enkephalinase,Kidney-Brush-Border Neutral Proteinase,Membrane Metallo-Endopeptidase,Atriopeptidase,CD10 Antigen,Enkephalinase-24.11,Neutral Endopeptidase,Neutral Endopeptidase 24.11,Thermolysin-Like Metalloendopeptidase,YGG-Forming Enzyme,Antigen, CD10,Carboxypeptidase, Enkephalin Dipeptidyl,Dipeptidyl Carboxypeptidase, Enkephalin,Endopeptidase 24.11,Endopeptidase 24.11, Neutral,Endopeptidase, Neutral,Enkephalinase 24.11,Enzyme, YGG-Forming,Kidney Brush Border Neutral Proteinase,Membrane Metallo Endopeptidase,Metallo-Endopeptidase, Membrane,Metalloendopeptidase, Thermolysin-Like,Neutral Proteinase, Kidney-Brush-Border,Thermolysin Like Metalloendopeptidase,YGG Forming Enzyme
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
October 2005, Diseases of the colon and rectum,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
January 2009, Pathobiology : journal of immunopathology, molecular and cellular biology,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
January 2016, OncoTargets and therapy,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
September 2020, World journal of surgical oncology,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
June 2010, International journal of colorectal disease,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
March 2009, International journal of colorectal disease,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
January 2016, Diseases of the colon and rectum,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
August 2017, United European gastroenterology journal,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
January 2007, Anticancer research,
Takamitsu Sasaki, and Hiroki Kuniyasu, and Yi Luo, and Rina Fujiwara, and Misaho Kitayoshi, and Eriko Tanabe, and Daisuke Kato, and Satoshi Shinya, and Kiyomu Fujii, and Hitoshi Ohmori, and Yuichi Yamashita
August 2013, International journal of colorectal disease,
Copied contents to your clipboard!